drugset / Trial / NCT01026818

A Study of Tadalafil After Radical Prostatectomy

NCT01026818 ↗

Phase 4 Completed 583 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will include patients with localized prostate cancer who experience erectile dysfunction following bilateral nerve-sparing radical prostatectomy. Patients will be randomly assigned to three treatment arms: Tadalafil 5 mg once a day, Tadalafil 20 mg on demand (prior to anticipated sexual activity), and placebo. Patients will stay on therapy for 9 months and after withdrawal of medication for 6 weeks, patients will be evaluated for recovery of unassisted erectile function (without medication). An open-label extension for three months will evaluate the responsiveness of all patients to Tadalafil 5 mg once a day. Further objectives are to evaluate the treatment satisfaction of the respective therapies.

Timeline

Start
2009-11
Primary completion
2012-10
Completion
2012-10

Outcome

Missed primary endpoint

registry Tadalafil 5 mg OaD vs Placebo; p = 0.675; Odds Ratio (OR) 1.14 (95% CI 0.63 to 2.06) NCT01026818 ↗

registry Tadalafil 20 mg PRN vs Placebo; p = 0.704; Odds Ratio (OR) 0.89 (95% CI 0.48 to 1.65) NCT01026818 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral
Subject Tadalafil Small molecule 20 mg Oral

Indications